MarketCap
Facebook
X
Telegram
Eli Lilly and Company EPS Ratio | LLY
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 | 11.8 | 5.82 | 6.93 | 6.15 | 6.82 | 8.93 | 3.14 | -0.19 | 2.59 | 2.27 | 2.23 | 4.33 | 3.67 | 3.9 | 4.58 | 3.94 | -1.89 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23 | -1.89 | 5.44 |
Quarterly EPS Ratio Eli Lilly and Company
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.95 | 8.27 | 6.22 | 6.3 | 3.07 | 1.08 | 3.29 | 2.49 | -0.06 | 1.96 | 1.49 | - | 1.61 | 1.06 | 2.11 | - | 1.22 | 1.53 | 1.49 | - | 1.33 | 1.56 | 1.6 | 1.64 | 1.37 | 1.44 | 4.33 | 1.11 | 1.13 | -0.25 | 1.16 | -1.58 | 0.53 | 0.96 | -0.1 | 0.73 | 0.74 | 0.71 | 0.42 | 0.45 | 0.75 | 0.57 | 0.5 | 0.4 | 0.47 | 0.68 | 0.68 | 0.68 | 1.11 | 1.12 | 1.42 | 0.75 | 1.18 | 0.83 | 0.91 | - | 1.11 | 1.07 | 0.95 | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.27 | -1.58 | 1.56 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
-2 | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
-1.46 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-104 | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
-1.29 | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-2.76 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-2.06 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-2.96 | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
-18.6 | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-0.76 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-0.64 | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-1.98 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-0.47 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-3.35 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-3.19 | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
-0.79 | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Cellectis S.A.
CLLS
|
-0.67 | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 12.03 | 1.78 % | $ 3.59 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.01 | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.82 | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
-3.9 | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-0.94 | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
-23 | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-0.08 | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
-3.46 | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
-0.12 | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
-1.24 | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
-1.34 | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
6.59 | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
-0.0846 | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
-1.42 | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
15.5 | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
0.29 | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
0.06 | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
-0.76 | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
-1.8 | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
1.08 | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
-3.17 | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
-0.07 | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-0.34 | $ 10.12 | 0.4 % | $ 289 M | USA |
|
Foghorn Therapeutics
FHTX
|
-1.18 | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
67.9 | $ 13.76 | 4.13 % | $ 11.5 B |  India |